Clinical Trial Update: A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Phase 2 multi-dose study evaluating subcutaneous AMG 108 in rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• AMG 108

Snippet

Sponsor: Amgen | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED